154 related articles for article (PubMed ID: 22718300)
21. Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques.
Kaifi JT; Kunkel M; Das A; Harouaka RA; Dicker DT; Li G; Zhu J; Clawson GA; Yang Z; Reed MF; Gusani NJ; Kimchi ET; Staveley-O'Carroll KF; Zheng SY; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):699-708. PubMed ID: 25807199
[TBL] [Abstract][Full Text] [Related]
22. Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy.
Mitra R; Chao O; Urasaki Y; Goodman OB; Le TT
BMC Cancer; 2012 Nov; 12():540. PubMed ID: 23171028
[TBL] [Abstract][Full Text] [Related]
23. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Hu B; Goldkorn A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1257-60. PubMed ID: 25199875
[TBL] [Abstract][Full Text] [Related]
25. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
26. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.
Chan F; Goodman O; Fink L; Vogelzang NJ; Pomerantz D; Khoury JD
Arch Pathol Lab Med; 2010 Jan; 134(1):120-3. PubMed ID: 20073615
[TBL] [Abstract][Full Text] [Related]
27. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Chen CL; Mahalingam D; Osmulski P; Jadhav RR; Wang CM; Leach RJ; Chang TC; Weitman SD; Kumar AP; Sun L; Gaczynska ME; Thompson IM; Huang TH
Prostate; 2013 Jun; 73(8):813-26. PubMed ID: 23280481
[TBL] [Abstract][Full Text] [Related]
28. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
29. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
30. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
[TBL] [Abstract][Full Text] [Related]
32. Detection of circulating tumor cells in men with localized prostate cancer.
Seiden MV; Kantoff PW; Krithivas K; Propert K; Bryant M; Haltom E; Gaynes L; Kaplan I; Bubley G; DeWolf W
J Clin Oncol; 1994 Dec; 12(12):2634-9. PubMed ID: 7527455
[TBL] [Abstract][Full Text] [Related]
33. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
34. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.
Varillas JI; Zhang J; Chen K; Barnes II; Liu C; George TJ; Fan ZH
Theranostics; 2019; 9(5):1417-1425. PubMed ID: 30867841
[No Abstract] [Full Text] [Related]
35. Identification and characterization of circulating prostate carcinoma cells.
Wang ZP; Eisenberger MA; Carducci MA; Partin AW; Scher HI; Ts'o PO
Cancer; 2000 Jun; 88(12):2787-95. PubMed ID: 10870062
[TBL] [Abstract][Full Text] [Related]
36. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.
Chen JF; Ho H; Lichterman J; Lu YT; Zhang Y; Garcia MA; Chen SF; Liang AJ; Hodara E; Zhau HE; Hou S; Ahmed RS; Luthringer DJ; Huang J; Li KC; Chung LW; Ke Z; Tseng HR; Posadas EM
Cancer; 2015 Sep; 121(18):3240-51. PubMed ID: 25975562
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression.
Palermo G; Bassi P; Racioppi M; Recupero SM; Sacco E; Campetella M; Canu G; Pinto F
Minerva Urol Nefrol; 2020 Apr; 72(2):214-222. PubMed ID: 31144490
[TBL] [Abstract][Full Text] [Related]
38. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells.
Santos MF; Mannam VK; Craft BS; Puneky LV; Sheehan NT; Lewis RE; Cruse JM
Exp Mol Pathol; 2014 Jun; 96(3):367-74. PubMed ID: 24731923
[TBL] [Abstract][Full Text] [Related]
40. AR-V7 expression in circulating tumor cells as a potential prognostic marker in metastatic hormone-sensitive prostate cancer.
Josefsson A; Damber JE; Welén K
Acta Oncol; 2019 Nov; 58(11):1660-1664. PubMed ID: 31286815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
